- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 18 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.2: 6 residues within 4Å:- Chain A: T.108, N.234, T.236
- Chain G: R.457, K.462, E.465
No protein-ligand interaction detected (PLIP)NAG-NAG.3: 4 residues within 4Å:- Chain A: N.717, L.922, Q.926, Q.1071
No protein-ligand interaction detected (PLIP)NAG-NAG.4: 4 residues within 4Å:- Chain A: N.801, S.803, Q.804, Q.935
No protein-ligand interaction detected (PLIP)NAG-NAG.5: 5 residues within 4Å:- Chain A: N.1098, G.1099, T.1100, H.1101, F.1103
No protein-ligand interaction detected (PLIP)NAG-NAG.6: 2 residues within 4Å:- Chain A: I.1132, N.1134
No protein-ligand interaction detected (PLIP)NAG-NAG.7: 4 residues within 4Å:- Chain A: N.122, T.124, N.125, V.127
No protein-ligand interaction detected (PLIP)NAG-NAG.9: 7 residues within 4Å:- Chain A: R.457, S.459, N.460, K.462, E.465
- Chain D: T.108, N.234
No protein-ligand interaction detected (PLIP)NAG-NAG.10: 4 residues within 4Å:- Chain D: N.717, L.922, Q.926, Q.1071
No protein-ligand interaction detected (PLIP)NAG-NAG.11: 4 residues within 4Å:- Chain D: N.801, S.803, Q.804, Q.935
No protein-ligand interaction detected (PLIP)NAG-NAG.12: 5 residues within 4Å:- Chain D: N.1098, G.1099, T.1100, H.1101, F.1103
No protein-ligand interaction detected (PLIP)NAG-NAG.13: 2 residues within 4Å:- Chain D: I.1132, N.1134
No protein-ligand interaction detected (PLIP)NAG-NAG.14: 4 residues within 4Å:- Chain D: N.122, T.124, N.125, V.127
1 PLIP interactions:1 interactions with chain D- Hydrogen bonds: D:N.125
NAG-NAG.16: 8 residues within 4Å:- Chain D: R.457, S.459, N.460, K.462, E.465
- Chain G: T.108, N.234, T.236
No protein-ligand interaction detected (PLIP)NAG-NAG.17: 4 residues within 4Å:- Chain G: N.717, L.922, Q.926, Q.1071
No protein-ligand interaction detected (PLIP)NAG-NAG.18: 3 residues within 4Å:- Chain G: N.801, S.803, Q.804
No protein-ligand interaction detected (PLIP)NAG-NAG.19: 5 residues within 4Å:- Chain G: N.1098, G.1099, T.1100, H.1101, F.1103
No protein-ligand interaction detected (PLIP)NAG-NAG.20: 2 residues within 4Å:- Chain G: I.1132, N.1134
No protein-ligand interaction detected (PLIP)NAG-NAG.21: 4 residues within 4Å:- Chain G: N.122, T.124, N.125, V.127
1 PLIP interactions:1 interactions with chain G- Hydrogen bonds: G:N.125
- 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.22: 3 residues within 4Å:- Chain A: A.706, E.1072, N.1074
Ligand excluded by PLIPNAG.23: 4 residues within 4Å:- Chain A: F.59, S.60, N.61, P.631
Ligand excluded by PLIPNAG.24: 4 residues within 4Å:- Chain A: N.280, E.281, N.282
- Chain G: K.558
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain A: N.331, Q.580
Ligand excluded by PLIPNAG.26: 3 residues within 4Å:- Chain A: N.709, G.1131
- Chain D: D.796
Ligand excluded by PLIPNAG.27: 1 residues within 4Å:- Chain A: N.657
Ligand excluded by PLIPNAG.28: 1 residues within 4Å:- Chain A: N.616
Ligand excluded by PLIPNAG.29: 1 residues within 4Å:- Chain A: N.603
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain A: N.17, N.137
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain A: G.339, E.340, N.343
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain D: A.706, E.1072, N.1074
Ligand excluded by PLIPNAG.33: 4 residues within 4Å:- Chain D: F.59, S.60, N.61, P.631
Ligand excluded by PLIPNAG.34: 4 residues within 4Å:- Chain A: K.558
- Chain D: N.280, E.281, N.282
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain D: N.331, Q.580
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain D: N.709, G.1131
- Chain G: D.796
Ligand excluded by PLIPNAG.37: 1 residues within 4Å:- Chain D: N.657
Ligand excluded by PLIPNAG.38: 1 residues within 4Å:- Chain D: N.616
Ligand excluded by PLIPNAG.39: 1 residues within 4Å:- Chain D: N.603
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain D: N.17, N.137
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain D: G.339, E.340, N.343
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain G: A.706, E.1072, N.1074
Ligand excluded by PLIPNAG.43: 4 residues within 4Å:- Chain G: F.59, S.60, N.61, P.631
Ligand excluded by PLIPNAG.44: 4 residues within 4Å:- Chain D: K.558
- Chain G: N.280, E.281, N.282
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain G: N.331, Q.580
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain A: D.796
- Chain G: N.709, G.1131
Ligand excluded by PLIPNAG.47: 1 residues within 4Å:- Chain G: N.657
Ligand excluded by PLIPNAG.48: 1 residues within 4Å:- Chain G: N.616
Ligand excluded by PLIPNAG.49: 1 residues within 4Å:- Chain G: N.603
Ligand excluded by PLIPNAG.50: 2 residues within 4Å:- Chain G: N.17, N.137
Ligand excluded by PLIPNAG.51: 3 residues within 4Å:- Chain G: G.339, E.340, N.343
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cerutti, G. et al., Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Structure (2021)
- Release Date
- 2021-03-17
- Peptides
- Spike glycoprotein: ADG
1-57 Fab heavy chain: BEH
1-57 Fab light chain: CFI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AD
BG
CB
HE
DH
EC
LF
FI
G
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 18 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cerutti, G. et al., Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Structure (2021)
- Release Date
- 2021-03-17
- Peptides
- Spike glycoprotein: ADG
1-57 Fab heavy chain: BEH
1-57 Fab light chain: CFI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AD
BG
CB
HE
DH
EC
LF
FI
G